Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free CYTK Stock Alerts $63.75 -1.44 (-2.21%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$63.65▼$68.3550-Day Range$63.75▼$108.0652-Week Range$25.98▼$110.25Volume2.25 million shsAverage Volume2.99 million shsMarket Capitalization$6.57 billionP/E RatioN/ADividend YieldN/APrice Target$77.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside20.8% Upside$77.00 Price TargetShort InterestBearish14.63% of Float Sold ShortDividend StrengthN/ASustainability-0.94Upright™ Environmental ScoreNews Sentiment0.46Based on 17 Articles This WeekInsider TradingSelling Shares$10.77 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.45) to ($3.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.93 out of 5 starsMedical Sector230th out of 946 stocksPharmaceutical Preparations Industry101st out of 434 stocks 3.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $77.00, Cytokinetics has a forecasted upside of 20.8% from its current price of $63.75.Amount of Analyst CoverageCytokinetics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.63% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cytokinetics has recently increased by 5.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 69.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.94. Previous Next 3.0 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Cytokinetics this week, compared to 6 articles on an average week.Search Interest24 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows16 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 129% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,771,950.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Cytokinetics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.45) to ($3.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -11.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -11.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 16, 2024 | finance.yahoo.comCYTK Mar 2024 63.000 callMarch 19, 2024 | Weiss Ratings (Ad)The ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …March 15, 2024 | finance.yahoo.comCYTK Mar 2024 69.000 putMarch 15, 2024 | finance.yahoo.comCYTK Mar 2024 69.000 callMarch 15, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)March 15, 2024 | finance.yahoo.comCYTK Mar 2024 62.000 callMarch 15, 2024 | finance.yahoo.comCYTK Apr 2024 58.000 putMarch 19, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic RestructuringMarch 13, 2024 | investorplace.com7 Biotech Stocks to Buy as Sector Rotation Ramps UpMarch 13, 2024 | seekingalpha.comIonis stock jumps as MASH drug succeeds in mid-stage trialMarch 12, 2024 | ca.finance.yahoo.comCYTK Aug 2024 30.000 putMarch 12, 2024 | finance.yahoo.comCYTK Mar 2024 61.000 putMarch 12, 2024 | finance.yahoo.comQ4 2023 CytomX Therapeutics Inc Earnings CallMarch 11, 2024 | finance.yahoo.comCYTK Apr 2024 65.000 putMarch 11, 2024 | finance.yahoo.comCYTK Apr 2024 110.000 callMarch 10, 2024 | finance.yahoo.comCYTK Apr 2024 73.000 callMarch 10, 2024 | finance.yahoo.comCYTK Apr 2024 72.000 putMarch 9, 2024 | finance.yahoo.comCYTK Mar 2024 83.500 callMarch 9, 2024 | finance.yahoo.comCYTK Mar 2024 72.000 putMarch 7, 2024 | finance.yahoo.comCYTK Mar 2024 68.000 callMarch 4, 2024 | globenewswire.comCytokinetics to Participate in March Investor ConferencesMarch 1, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | markets.businessinsider.comOptimistic Outlook on Cytokinetics: Buy Rating Affirmed Amid Anticipated Growth and Strategic MilestonesMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics Amid Strong Clinical Progress and Strategic Commercial PreparationsFebruary 29, 2024 | finance.yahoo.comCytokinetics Full Year 2023 Earnings: Misses ExpectationsSee More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/19/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$77.00 High Stock Price Target$108.00 Low Stock Price Target$42.00 Potential Upside/Downside+20.8%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-6,988.63% Pretax Margin-6,988.63% Return on EquityN/A Return on Assets-65.08% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$7.53 million Price / Sales872.01 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-16.18Miscellaneous Outstanding Shares103,000,000Free Float99,091,000Market Cap$6.57 billion OptionableOptionable Beta0.69 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President & Director Comp: $1.14MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $463.75kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $776.99kMr. Andrew M. Callos (Age 68)Executive VP & Chief Commercial Officer Comp: $745.4kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Supply Chain Operations & Technical Operations Ms. Diane WeiserSenior Vice President of Corporate Communications & Investor RelationsMs. Kari K. Loeser J.D.VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTXIonis PharmaceuticalsNASDAQ:IONSApellis PharmaceuticalsNASDAQ:APLSIntra-Cellular TherapiesNASDAQ:ITCIJazz PharmaceuticalsNASDAQ:JAZZView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 273,565 shares on 3/11/2024Ownership: 10.696%Fisher Asset Management LLCBought 536,046 shares on 3/5/2024Ownership: 0.520%Fady Ibraham MalikSold 32,604 sharesTotal: $2.20 M ($67.56/share)American International Group Inc.Sold 335 shares on 2/28/2024Ownership: 0.052%Teachers Retirement System of The State of KentuckySold 3,155 shares on 2/26/2024Ownership: 0.056%View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 15 Wall Street analysts have issued 12 month price targets for Cytokinetics' shares. Their CYTK share price targets range from $42.00 to $108.00. On average, they expect the company's share price to reach $77.00 in the next twelve months. This suggests a possible upside of 20.8% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2024? Cytokinetics' stock was trading at $83.49 at the start of the year. Since then, CYTK stock has decreased by 23.6% and is now trading at $63.75. View the best growth stocks for 2024 here. Are investors shorting Cytokinetics? Cytokinetics saw a increase in short interest in February. As of February 29th, there was short interest totaling 14,530,000 shares, an increase of 5.1% from the February 14th total of 13,830,000 shares. Based on an average daily volume of 3,700,000 shares, the short-interest ratio is presently 3.9 days. Approximately 14.6% of the company's stock are short sold. View Cytokinetics' Short Interest. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CYTK earnings forecast. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.03) by $0.35. The biopharmaceutical company had revenue of $1.70 million for the quarter, compared to analyst estimates of $7.62 million. The business's revenue was down 10.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.45) EPS. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), American Century Mid Cap Growth Impact (MID), Fidelity Disruptive Medicine ETF (FMED), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO) and Principal Healthcare Innovators ETF (BTEC). What guidance has Cytokinetics issued on next quarter's earnings? Cytokinetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million. What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.24%), Vanguard Group Inc. (10.70%), Price T Rowe Associates Inc. MD (3.31%), RTW Investments LP (2.58%), Northern Trust Corp (1.08%) and First Turn Management LLC (0.82%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.